Details

Autor(en) / Beteiligte

• Marra, Alexandre R
• Miraglia, João Luiz
• Malheiro, Daniel Tavares
• Guozhang, Yang
• Teich, Vanessa Damazio
• Victor, Elivane da Silva
• Pinho, João Renato Rebello
• Cypriano, Adriana
• Vieira, Laura Wanderly
• Polonio, Miria
• Ornelas, Rafael Herrera
• de Oliveira, Solange Miranda
• Borges, Flavio Araujo
• Oler, Silvia Cristina Cassiano
• Ricardo, Victória Catharina Volpe
• Maezato, Aline Miho
• Callado, Gustavo Yano
• Schettino, Guilherme de Paula Pinto
• de Oliveira, Ketti Gleyzer
• Santana, Rúbia Anita Ferraz
• Malta, Fernanda de Mello
• Amgarten, Deyvid
• Boechat, Ana Laura
• Kobayashi, Takaaki
• Salinas, Jorge L
• Edmond, Michael B
• Rizzo, Luiz Vicente

Titel

Longer-term effectiveness of a heterologous coronavirus disease 2019 (COVID-19) vaccine booster in healthcare workers in Brazil

Ist Teil von

• Antimicrobial stewardship & healthcare epidemiology : ASHE, 2023, Vol.3 (1), p.e104-e104, Article e104

Ort / Verlag

England: Cambridge University Press

Erscheinungsjahr

2023

Quelle

Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals

Beschreibungen/Notizen

• To compare the long-term vaccine effectiveness between those receiving viral vector [Oxford-AstraZeneca (ChAdOx1)] or inactivated viral (CoronaVac) primary series (2 doses) and those who received an mRNA booster (Pfizer/BioNTech) (the third dose) among healthcare workers (HCWs). We conducted a retrospective cohort study among HCWs (aged ≥18 years) in Brazil from January 2021 to July 2022. To assess the variation in the effectiveness of booster dose over time, we estimated the effectiveness rate by taking the log risk ratio as a function of time. Of 14,532 HCWs, coronavirus disease 2019 (COVID-19) was confirmed in 56.3% of HCWs receiving 2 doses of CoronaVac vaccine versus 23.2% of HCWs receiving 2 doses of CoronaVac vaccine with mRNA booster ( < .001), and 37.1% of HCWs receiving 2 doses of ChAdOx1 vaccine versus 22.7% among HCWs receiving 2 doses of ChAdOx1 vaccine with mRNA booster ( < .001). The highest vaccine effectiveness with mRNA booster was observed 30 days after vaccination: 91% for the CoronaVac vaccine group and 97% for the ChAdOx1 vaccine group. Vacine effectiveness declined to 55% and 67%, respectively, at 180 days. Of 430 samples screened for mutations, 49.5% were SARS-CoV-2 delta variants and 34.2% were SARS-CoV-2 omicron variants. Heterologous COVID-19 vaccines were effective for up to 180 days in preventing COVID-19 in the SARS-CoV-2 delta and omicron variant eras, which suggests the need for a second booster.